Iovance (IOVA) CFO Corleen Roche Receives 450k-Share Equity Awards

Rhea-AI Filing Summary

Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics (IOVA), reported equity awards dated 08/06/2025. The Form 4 discloses a grant of 300,000 stock options with a $2.58 exercise price and an expiration date listed as 08/06/2035, and 150,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. Both awards are held directly following the reported transactions. The awards vest only if the reporting person remains employed: one-third vests on the one-year anniversary of the grant and the remaining two-thirds vest in eight equal quarterly installments over the following two years. The form is signed by Corleen Roche on 08/08/2025.

Positive

• 300,000 stock options granted at a $2.58 exercise price (direct beneficial ownership)
• 150,000 RSUs granted, each representing a contingent right to one share of common stock
• Clear vesting schedule: one-third at one-year anniversary, remaining two-thirds in eight equal quarterly installments over the following two years

Negative

• Awards are contingent on continued employment (vesting occurs only if the reporting person remains employed)
• 450,000 underlying shares in total (300,000 options + 150,000 RSUs) could be issued upon exercise/settlement

Insights

Financial Analyst

TL;DR Routine CFO equity grants: 300,000 options and 150,000 RSUs—limited immediate financial disclosure beyond grant terms.

The Form 4 documents standard long-term incentive awards to CFO Corleen Roche on 08/06/2025: 300,000 stock options at a $2.58 strike with an 08/06/2035 expiration and 150,000 RSUs convertible to common shares. Both holdings are reported as direct beneficial ownership following the transaction. The disclosed vesting schedule (one-third at one year; remainder in eight quarterly installments over two years) ties realization to continued employment rather than performance metrics. From a financial perspective, the filing communicates grant size, strike, and vesting but provides no valuation, tax treatment, or acceleration provisions.

Compensation/Governance Specialist

TL;DR Grants are employment-contingent with multi-year vesting; governance implications are routine and disclosure is complete for a Form 4.

The filing clearly states the nature and schedule of the awards: 300,000 stock options and 150,000 RSUs, both held directly. Each RSU equals a contingent right to one share. Vesting requires continued employment and is staggered (1/3 after one year, remaining in eight quarterly installments). The option term shown (to 08/06/2035) indicates a ten-year contractual horizon from grant date. The Form 4 provides the governance-relevant facts investors need regarding timing and ownership; no accelerated vesting or other special conditions are disclosed in the explanation section.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roche Corleen M.

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.58	08/06/2025		A		300,000		(1)	08/06/2035	Common stock	300,000	$0.00	300,000	D
Restricted Stock Units	(2)	08/06/2025		A		150,000		(1)	(1)	Common stock	150,000	$0.00	150,000	D

Explanation of Responses:

1. Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Corleen Roche	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Corleen Roche report on the IOVA Form 4?

The report discloses grants dated 08/06/2025 of 300,000 stock options at a $2.58 exercise price and 150,000 RSUs; both are reported as direct holdings.

When do the options and RSUs vest for IOVA CFO Corleen Roche?

Vesting is employment-contingent: one-third vests on the one-year anniversary of the grant, with the remainder vesting in eight equal quarterly installments over the next two years.

Do the RSUs convert to shares for Iovance (IOVA)?

Yes. The filing states each RSU represents a contingent right to receive one share of the issuer's common stock.

What is the option term and exercise price reported on the Form 4?

The stock options show an exercise price of $2.58 and an expiration date listed as 08/06/2035.

When was the Form 4 signed by the reporting person?

The Form 4 is signed by Corleen Roche on 08/08/2025.